New strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis  

作　　者：Tsvetelina Velikova Boris Krastev Milena Gulinac Miroslav Zashev Vasko Graklanov Milena Peruhova 

机构地区：[1]Medical Faculty,Sofia University St.Kliment Ohridski,Sofia 1407,Bulgaria [2]Medical Center Nadezhda,Medical Center Nadezhda,Sofia 1407,Bulgaria [3]General and Clinical Pathology,Medical University of Plovdiv,Plovdiv 4002,Bulgaria [4]Department of General Surgery,University Hospital“Heart and Brain”,Burgas 8000,Bulgaria [5]First Department of Internal Diseases,Medical University of Plovdiv,Plovdiv 4000,Bulgaria [6]Department of Hematology,University Hospital“St.George”,Plovdiv 4000,Bulgaria [7]Division of Gastroenterology,University Hospital“Heart and Brain”,Burgas 1000,Bulgaria

出　　处：《World Journal of Clinical Cases》2024年第6期1050-1062,共13页世界临床病例杂志

基　　金：Supported by the European Union-NextGenerationEU,through the National Recovery and Resilience Plan of the Republic of Bulgaria,No.BG-RRP-2.004-0008.

摘　　要：Immune-checkpoint inhibitor-mediated colitis(IMC)is an increasingly recognized adverse event in cancer immunotherapy,particularly associated with immune checkpoint inhibitors(ICIs)such as anti-cytotoxic T-lymphocyte antigen-4 and anti-programmed cell death protein-1 antibodies.As this revolutionary immunotherapy gains prominence in cancer treatment,understanding,diagnosing,and effectively managing IMC becomes paramount.IMC represents a unique challenge due to its immune-mediated nature and potential for severe complications.However,a precise picture of IMC pathophysiology is currently unavailable.Therefore,we aimed to summarize the existing data while acknowledging the need for further research.This comprehensive review explores the mechanisms underlying ICIs,gastrointestinal adverse effects,and,in particular,IMC’s incidence,prevalence,and features.Our review also emphasizes the importance of recognizing IMC’s distinct clinical and histopathological features to differentiate it from other forms of colitis.Furthermore,this paper highlights the urgentneed for evolving diagnostic methods,therapeutic strategies,and a multidisciplinary approach to effectively manage IMC.

关 键 词：Immune-checkpoint inhibitors Immune-checkpoint inhibitor-mediated colitis Inhibitor-mediated colitis management Immunotherapy-associated colitis Checkpoint inhibitor-induced colitis Gastrointestinal adverse effects Checkpoint inhibitor toxicity Inhibitor-mediated colitis therapy 

分 类 号：R738.1[医药卫生—肿瘤]